Early-stage companies tend to focus on the science and the next funding round. The regulatory plan often comes later, sometimes after a first study is already designed. That order is understandable, but it can be expensive, because the pathway to market shapes which studies are needed, how long they take and what investors will want to see.
This article covers, at a general level, the questions small teams should ask early. Every product is different, so treat it as a starting point for conversations with qualified regulatory advisers.
Start With Classification, Not Submission
Before anyone drafts a submission, the team needs to know what the product is in the eyes of the regulator. A small molecule, a biologic, a device, software or a combination each follows a different route.
For devices, classification by risk drives almost everything else. Lower-risk devices may be exempt from premarket review or may only need a 510(k). Higher-risk devices usually need a premarket approval application. For drugs and biologics, the path usually runs through an investigational new drug application and then a marketing application, with phases of clinical work in between.
Combination products add a layer. A drug-coated implant or a prefilled injector is assigned a lead FDA center based on its primary mode of action, and sponsors can ask the agency for a formal designation when that is unclear. Settling this early keeps teams from building evidence for the wrong reviewers.
Choosing Between 510(k), De Novo and PMA
For device startups, this is one of the biggest early decisions. A simplified view:
| Pathway | Typical fit | What it hinges on |
| 510(k) | Moderate-risk devices similar to one already legally marketed | Showing substantial equivalence to a predicate device |
| De Novo | Novel low- to moderate-risk devices with no suitable predicate | Showing that general and special controls are enough to assure safety and effectiveness |
| PMA | High-risk (Class III) devices | Valid scientific evidence, usually including clinical data |
The 510(k) route is often seen as faster and cheaper, which tempts teams to stretch for a predicate. If the predicate differs too much in intended use or technology, the agency may find the device not substantially equivalent, and months are lost. A De Novo request takes more work up front, but a successful one creates a classification that later products, including your own next generation, can use as a predicate.
PMA is a different scale of effort, usually requiring an investigational device exemption for a pivotal study and quality systems ready for inspection.
Use the Pre-Submission Program Early
One of the most useful tools for small companies is the Q-Submission program, which includes Pre-Submission meetings for devices. A sponsor sends specific questions and supporting material, and the FDA gives written feedback, often followed by a meeting. Drug and biologic sponsors have a similar option in pre-IND meetings.
These meetings work best when questions are narrow. “Is our device ready?” gets a vague answer. “Is this bench testing plan adequate to support equivalence to our proposed predicate?” gets something you can act on. Good topics include:
- Which pathway fits, and whether a proposed predicate is reasonable
- What nonclinical testing is expected
- Whether clinical data will be needed, and in what design
- How software, cybersecurity or human factors will be reviewed
Because framing matters so much, some small sponsors bring in a group such as Health Policy Associates, a consulting firm in Dedham, Massachusetts that supports Pre-Submission, 510(k) and IDE work, along with clinical trial and data integrity services. Either way, the goal is written feedback that reduces uncertainty in your plan.
Plan Evidence Backward From the Decision
A common mistake is to run studies first and figure out later how they fit a submission. A better approach starts with the regulatory decision: ask what the reviewer will need to conclude, then list the evidence that supports each conclusion. For a device, that may include biocompatibility, electrical safety, software validation, bench performance and possibly clinical data. For a drug, it includes nonclinical safety, manufacturing data and a clinical program sized to your intended claims.
Some practical habits help:
- Write the intended use early and keep it stable. Changing indications midway can invalidate studies already done.
- Build quality systems early. Design controls are far easier to set up at the start than to recreate later.
- Protect data integrity from day one. Clean audit trails, monitored sites and documented decisions make later review smoother.
- Budget for surprises. Plan time and cash for at least one round of additional information requests.
Expedited Programs and When They Matter
The FDA offers several programs that can shorten timelines or increase interaction with reviewers. Device makers may qualify for the Breakthrough Devices Program if a product could offer more effective treatment or diagnosis of a life-threatening or irreversibly debilitating condition. Drug and biologic sponsors have options such as Fast Track, Breakthrough Therapy designation, Accelerated Approval and Priority Review.
These programs are worth exploring, but they don’t replace the need for solid evidence. Apply when the criteria clearly fit, not to signal momentum to investors. The agency’s own guidance documents and program pages at the U.S. Food and Drug Administration site are the best place to check current eligibility rules, since they are updated over time.
Make Regulatory Part of the Business Plan
Regulatory strategy also affects valuation, partnering and fundraising. Investors often ask which pathway a company expects, what the agency has already said and how the clinical plan supports commercial goals.
A short, regularly updated regulatory strategy document can answer those questions in one place: classification, expected pathway, agency feedback so far, the evidence plan, major risks and next interactions.
None of this replaces expert advice tailored to your product, and rules change over time. What early planning does is give a small team a clear map, so the science, the studies and the submission all point toward the same decision.
